Form 4: Sarepta Exec's Tax Withholding on RSU Vesting

Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss had 974 shares withheld for tax obligations related to restricted stock unit vesting.

Summary

• Cristin Rothfuss, Executive Vice President and General Counsel of Sarepta Therapeutics, Inc. (SRPT), reported a transaction on March 11, 2026.
• The transaction involved the disposition of 974 shares of Common Stock at a price of $17.03 per share.
• These shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) that were granted on March 10, 2025.
• Following this transaction, Ms. Rothfuss beneficially owns 137,544 shares of Sarepta Therapeutics Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting a standard compensation practice for executives through equity vesting and associated tax withholding, with no material impact on the company's operational or financial outlook.

Positives

• The vesting of restricted stock units (RSUs) indicates the realization of equity compensation for the executive.

Negatives

• A reduction of 974 shares from the executive's direct beneficial ownership due to tax withholding.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions like tax-related withholdings are common for executives receiving equity compensation and generally do not signal significant shifts in company strategy or performance within the biotechnology industry.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction related to executive compensation.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine tax-related share withholding upon RSU vesting for an executive. It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation event and does not alter the fundamental investment thesis for Sarepta Therapeutics.

Keywords

Sarepta Therapeutics, SRPT, Form 4, insider transaction, stock withholding, restricted stock units, RSU vesting, executive compensation